Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up

BACKGROUND: Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizum...

Descripción completa

Detalles Bibliográficos
Autores principales: De Rossi, Nicola, Scarpazza, Cristina, Filippini, Chiara, Cordioli, Cinzia, Rasia, Sarah, Mancinelli, Chiara Rosa, Rizzoni, Damiano, Romanelli, Giuseppe, Cossi, Stefania, Vettoretto, Nereo, Bove, Sergio, Manfredini, Silvano, Beindorf, Eva Andrea, Mosca, Carlo, Scipione, Vittorio, Flamminio, Gigliola, Albini, Elena Albini, Giansiracusa, Paola, Capra, Ruggero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366117/
https://www.ncbi.nlm.nih.gov/pubmed/32838235
http://dx.doi.org/10.1016/j.eclinm.2020.100459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366117/
https://www.ncbi.nlm.nih.gov/pubmed/32838235
http://dx.doi.org/10.1016/j.eclinm.2020.100459

Ejemplares similares